Chapter 35 — Case Study 2: The PROTAC Revolution — Closing the Thalidomide Arc

"The same molecule that caused 10,000 birth defects in the 1960s is now the foundation of an exciting new drug class. Thalidomide's history is a story of redemption: from teratogen to therapeutic, from chemistry's worst lesson to its most ambitious possibility." — paraphrase of a 2024 medicinal chemistry review

The thalidomide arc — introduced in Chapter 1 of this textbook, deepened in Chapter 27 case study 1, and now closed here in Chapter 35 — is one of the most remarkable stories in modern pharmacology. It traces a single molecule from tragedy (1957-1961), through redemption as a multiple myeloma drug (1990s), to its current role as the foundation of PROTACs — a new class of drugs that don't merely inhibit disease-driving proteins but actively destroy them.

This case study traces the PROTAC revolution from its scientific roots to the dozens of drugs now in clinical trials.

What is a PROTAC?

A PROTAC (proteolysis-targeting chimera) is a heterobifunctional small molecule with three components:

1. Target ligand: binds a disease-causing protein (e.g., a cancer-driving kinase, an estrogen receptor in breast cancer, a misfolded protein).
2. Linker: a flexible chain connecting the two ligands (typically PEG-based or alkyl).
3. E3 ligase ligand: binds an E3 ubiquitin ligase (most commonly cereblon, but also VHL, IAP, MDM2).

When the PROTAC binds both targets simultaneously (forming a "ternary complex" with the target protein and the E3 ligase), the E3 ligase tags the target with ubiquitin (a small protein that marks substrates for degradation). The ubiquitinated target is then destroyed by the proteasome — the cell's protein-degradation machine.

The PROTAC itself is catalytic: it dissociates after the ubiquitination, free to bind another target molecule. One PROTAC can recruit cereblon to ubiquitinate hundreds of target molecules.

The thalidomide-cereblon connection

In 2010, Ito et al. (RIKEN, Japan) discovered that thalidomide binds cereblon (CRBN), a substrate adapter for the CRL4 E3 ubiquitin ligase complex. This explained the mechanism of thalidomide-induced birth defects: thalidomide bound cereblon and recruited it to ubiquitinate specific transcription factors (SALL4, IKZF1) needed for limb development. Without these factors, limbs failed to form.

The discovery gave thalidomide a target. And it suggested a paradigm: if thalidomide could recruit cereblon to a teratogenically harmful target, why not deliberately design molecules to recruit cereblon to disease-causing targets?

The PROTAC concept (2001 → 2015)

The PROTAC concept was first proposed by Crews and Deshaies in 2001 (J. Am. Chem. Soc.): - Use a small molecule to physically bridge a target protein and an E3 ligase. - The bridging triggers ubiquitination and proteasomal degradation. - The drug is not an inhibitor — it's a catalyst for protein destruction.

For ~14 years, PROTACs were a research curiosity. The field needed: - Efficient E3 ligase ligands (the cereblon-thalidomide connection from 2010). - Knowledge of how to design ternary complexes. - Suitable target ligands.

By 2015, all three were available. The PROTAC field exploded.

How PROTACs work mechanistically

Mechanism of PROTAC-induced degradation: 1. PROTAC enters cell cytoplasm. 2. PROTAC binds target protein at one end (with affinity ~nM-μM). 3. PROTAC binds E3 ligase (cereblon) at the other end (with affinity ~nM-μM). 4. Ternary complex forms: target — PROTAC — E3 ligase. 5. The E3 ligase complex then transfers ubiquitin to surface lysines of the target. 6. Multiple ubiquitins are added (polyubiquitination) — a "kill" signal. 7. The 26S proteasome recognizes the polyubiquitinated target and degrades it. 8. The PROTAC dissociates and can bind another target.

The chemistry: thia-Michael, amide formation, etc. (Chapters 26-29 chemistry) is used to make the PROTAC molecule. The biology: enzyme-catalyzed protein degradation.

Why PROTACs are exciting

PROTACs offer several advantages over traditional inhibitors:

1. Catalytic mechanism

A small amount of PROTAC can degrade large amounts of target protein. This means: - Lower drug doses. - Less toxicity from off-target effects. - Sustained effect even after drug clearance.

2. "Undruggable" targets

Some proteins lack a catalytic active site or a clear binding pocket — they're hard to inhibit with traditional drugs. PROTACs can target proteins with only a "ligandable surface" (a place where a small molecule can bind, even if it doesn't disrupt function).

Example: transcription factors (e.g., MYC, STAT3) have been considered undruggable for 50+ years. PROTACs may target them by recruiting them for degradation rather than trying to inhibit their function directly.

3. Drug resistance

Cancer cells often evolve resistance to traditional kinase inhibitors by mutating the kinase's binding site. But PROTACs can target multiple binding sites or overcome resistance by destroying the kinase entirely.

Example: ibrutinib resistance in B-cell cancers can be overcome by a PROTAC that degrades BTK rather than just inhibiting it.

4. Selectivity

By choosing the E3 ligase carefully (cereblon vs. VHL vs. IAP vs. MDM2), PROTACs can selectively degrade targets in specific cells or tissues, depending on which E3 ligase is most expressed.

Clinical PROTACs (as of 2024-2025)

ARV-471 (vepdegestrant, Arvinas)

• Target: estrogen receptor (ER+) in breast cancer.
• Mechanism: degrades ER, depriving cancer cells of growth signal.
• Phase: Phase III as of 2024.
• Use: late-stage breast cancer, especially when fulvestrant (a small-molecule ER degrader) has failed.

ARV-110 (bavdegalutamide, Arvinas)

• Target: androgen receptor (AR) in prostate cancer.
• Phase: Phase II.
• Use: prostate cancer resistant to androgen receptor inhibitors.

CC-90011 (Bristol Myers Squibb)

• Target: LSD1 (a histone demethylase implicated in some cancers).
• Phase: Phase II.

Multiple BTK PROTACs

• Target: BTK kinase (the same target as ibrutinib).
• Goal: overcome ibrutinib resistance in B-cell cancers.
• Phase: multiple in early clinical development.

Beyond cancer: - Neurodegenerative disease PROTACs: targeting tau (Alzheimer's), α-synuclein (Parkinson's). - Immunology PROTACs: targeting cytokine receptors, transcription factors. - Antiviral PROTACs: targeting viral proteins.

The PROTAC field has expanded rapidly: from 0 clinical candidates in 2015 to ~50+ in trials in 2024.

Design challenges and chemistry

PROTAC design has unique challenges:

Linker design

The linker connects the two ligands. Key considerations: - Length: must allow simultaneous binding to both targets (the ternary complex must be geometrically feasible). - Flexibility: too rigid prevents productive binding; too flexible reduces efficacy. - Composition: typically alkyl chain or PEG (polyethylene glycol). Fluorinated linkers are also explored. - Polarity: too lipophilic = poor cell penetration; too polar = poor membrane crossing.

Linker length is often 4-10 atoms. Longer linkers can be needed for some target geometries.

Ternary complex stability

The ternary complex is critical. If the target and E3 ligase don't align productively, ubiquitination doesn't happen.

The "hook effect": at very high PROTAC concentrations, the drug saturates both target and E3 separately, preventing the ternary complex. Optimal PROTAC concentration is intermediate.

This non-linear behavior is unique to PROTACs and complicates dose-response.

Cell penetration

PROTACs are larger than traditional drugs (typical MW 700-1000, beyond Lipinski). Cell penetration is a concern.

Strategies: - Optimize lipophilicity (logP). - Use charged/zwitterionic linkers for solubility while maintaining penetration. - Cell-permeable lipid conjugates. - Some PROTACs require specific transporters (UCB analogs use OATP).

Safety

PROTACs can have unexpected effects from "off-target degradation": degrading proteins other than the intended target. This is particularly a concern for cereblon (which has many natural substrates).

Some PROTACs use "engineered" cereblon ligands designed to be highly selective for the target only, minimizing off-target degradation.

The thalidomide story is closed

The thalidomide arc closes here:

• 1957-1961: Thalidomide caused 10,000 cases of phocomelia (severely underdeveloped limbs).
• 1961: Thalidomide withdrawn worldwide.
• 1962: Kefauver-Harris Amendment requires FDA pre-marketing safety testing.
• 1990s: Lenalidomide (a thalidomide analog) approved for multiple myeloma.
• 2010: Cereblon identified as the thalidomide target. The chemistry of birth defects clarified.
• 2015+: PROTACs designed using thalidomide and lenalidomide as cereblon-binding ligands.
• 2024+: Multiple PROTACs in late-stage clinical trials. Thalidomide-like ligands are the most-used component.

The molecule that caused tragedy in 1960 now forms the foundation of a new drug class. Through deeper understanding of its mechanism, organic chemistry has redeemed thalidomide.

Lessons: - Every molecule has chemistry to teach. - Bad outcomes can drive better understanding; better understanding can lead to better drugs. - The chemistry that caused birth defects can, with deliberate design, treat cancer. - Thalidomide's story is a microcosm of pharmaceutical chemistry's power — and the importance of mechanism understanding.

Take-home

• PROTACs are heterobifunctional drugs that recruit E3 ubiquitin ligases (especially cereblon) to degrade disease-causing proteins.
• The mechanism: target-PROTAC-E3 ternary complex → polyubiquitination → proteasomal degradation. Catalytic.
• Thalidomide is the most-used cereblon ligand. The thalidomide-cereblon discovery (2010) launched the field.
• PROTACs target proteins that traditional inhibitors can't (transcription factors, scaffold proteins).
• Multiple PROTACs are in clinical trials (ARV-471 for ER+ breast cancer; ARV-110 for prostate cancer; many others).
• Design challenges: linker length, ternary complex formation, cell penetration, off-target degradation.
• The thalidomide arc is closed: from 1960 teratogen to 2025 therapeutic foundation. A story of chemistry's redemption.
• Mastery of Chapter 35's drug design principles, combined with the chemistry of Parts I-VII, is the foundation for understanding modern medicinal chemistry — including PROTACs and the future generations of drugs they will inspire.